Theoretical potential benefits (currently unproven for rheumatoid arthritis and not studied at microdose levels): Possible anti-inflammatory effects through modulation of immune pathways Weight reduction, which may indirectly benefit joint symptoms in overweight patients Cardiovascular risk reduction, relevant given increased cardiovascular disease risk in rheumatoid arthritis (established in type 2 diabetes populations at therapeutic doses only) [28] Improved metabolic parameters in patients with concurrent metabolic syndrome Known adverse effects of GLP-1 receptor agonists at standard doses include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, and abdominal discomfort (very common, affecting more than 1 in 10 patients) Hypoglycaemia : particularly when used with other glucose-lowering medications Injection site reactions : erythema, pruritus, or nodules Pancreatitis : rare but serious, requiring immediate medical attention if severe abdominal pain develops Gallbladder disease : increased risk of cholelithiasis and cholecystitis Thyroid effects : thyroid C-cell tumours observed in rodents
Calves, swine and sheep - 5 ml IM per 100 pounds of body weight
We offer personalised plans that include: Comprehensive health assessments Access to prescription GLP-1 injections such as Wegovy and Mounjaro Ongoing support from medical professionals Nutritional and behavioural guidance Quitting smoking is hard
Strains clearly listed (not just "proprietary blend") A better label includes the full strain name, not only the genus/species
& Mochly-Rosen, D
